Final answer:
Aggregates in Huntington's Disease can be removed or prevented by enhancing protein quality control mechanisms, using small molecules or antibodies to prevent aggregation, or applying gene therapy to lower mutant huntingtin levels. Supporting ongoing research is crucial for developing effective treatments.
Step-by-step explanation:
Aggregates in Huntington's Disease (HD) can be prevented or removed by targeting the aggregation process of the mutant huntingtin protein. One approach is to enhance the cellular protein quality control mechanisms, such as the ubiquitin-proteasome system and autophagy, which can identify and degrade misfolded proteins. Another strategy involves the use of small molecules or antibodies that specifically bind to the huntingtin protein and prevent it from aggregating. Additionally, gene therapy techniques that lower the levels of mutant huntingtin mRNA or protein may contribute to reducing the formation of aggregates.
It is also important to support ongoing research and clinical trials aimed at understanding the underlying mechanisms of protein aggregation in HD and developing new therapeutic approaches.